Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Carboplatin in Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy (JONIE4/JCaT)
jRCTs051180210Phase 3Active, not recruiting
- Start
- Jun 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of carboplatin in triple-negative breast cancer (TNBC). Primary endpoint: Disease-free survival. Started Jun 2020; status: active, not recruiting.
02
Drugs
carboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on jRCTs051180210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180210.